Pharmacists Perspective Faryal Faisal, PharmD The serious side effects look frightening on paper but are genuinely uncommon most patients complete a full year of semaglutide therapy without experiencing any of them
As a dual agonist, tirzepatide has demonstrated superior efficacy compared to selective GLP-1 receptor agonists in both glycemic control and weight reduction
5% Report Body Aches Those small, measurable steps reduce anxiety and lead to more explicit conversations with clinicians because you bring data, not guesswork
In the SURPASS-2 study, the three doses of tirzepatide (5, 10, and 15 mg once weekly) were tested with the GLP-1RA semaglutide (1 mg once weekly) as a comparator in patients not optimally controlled on monotherapy with metformin (71)
Book Consultation
Their analysis of seized products found bacterial contamination, incorrect chemical structures, and impurity levels that could cause serious adverse reactions